Sérgio Chacim holds a degree in Medicine from the Abel Salazar Institute of Biomedical Sciences (UP), having completed his specialization in Clinical Hematology at the Portuguese Institute of Oncology in Porto (IPO), where he has worked as a Consultant in the Hematology and Bone Marrow Transplant Service since 2006.

He carries out research activities in the Epigenetics and Cancer Biology Group, at the IPO Porto Research Center. He has experience in phase III clinical trials and is part of the Early Phase Trials group at IPO Porto.

He has been involved in the certification and implementation of CAR-T technology at IPO Porto since 2018.

He is a member of the Portuguese Society of Hematology, a medical expert appointed to the Health Technology Assessment Committee of INFARMED, and a member of the Pharmacy and Therapeutics Committee of IPO Porto. He has been a member of the executive committee of the Northern Section of the Brazilian Medical Association since 2023.